Core Viewpoint - The company, Yidu Tech (02158), continues to demonstrate confidence in its development and the AI healthcare sector through ongoing share buybacks, totaling over HKD 74 million since January 26, 2023 [1] Group 1: Share Buyback Activity - On February 26, Yidu Tech repurchased 382,000 shares at approximately HKD 5.97 per share, with a total expenditure of nearly HKD 2.3 million [1] - The company has completed 18 buybacks this year, reflecting a strong commitment to enhancing shareholder value [1] Group 2: Business Innovations and Developments - Yidu Tech's "Yidu Zhixun" clinical evidence-based intelligent system has entered the internal testing phase, aimed at meeting the real needs of clinical doctors and medical researchers [1] - The company is inviting frontline clinical doctors to participate in the experience and co-creation of this mini-program [1] Group 3: Recognition and Projects - The "Hainan Free Trade Port 'External Prevention of Input' Infectious Disease Monitoring and Early Warning" project, led by the Hainan Provincial Health Commission's Statistical Information Center with core technical support from Yidu Tech, was recognized as an excellent practice case in the healthcare sector [1]

医渡科技(02158)发布公告，于2026年2月26日斥资228.02万港元回购38.2万股。 ...

格隆汇2月26日丨医渡科技(02158.HK)公告，2月26日耗资228万港元回购38.2万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月26日斥资228.02万港元回购38.2万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

Core Insights - The report highlights changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies. Group 1: Recent Increases in Holdings - VITASOY INT'L (00345) saw an increase of 0.09%, bringing its latest holding percentage to 3.75% [1] - 恒生科技ETF (03032) increased by 0.04%, with a current holding of 18.49% [1] - 永升服务 (01995) experienced a rise of 0.01%, now holding 4.57% [1] - 南方东西精选 (03441) had the largest increase over five days at 18.46%, reaching 41.03% [4] - 喜相逢集团 (02473) increased by 10.04%, with a holding of 45.14% [4] - 兆易创新 (03986) rose by 4.95%, now at 6.65% [4] Group 2: Recent Decreases in Holdings - 南方恒生科技 (03033) experienced the largest decrease of -0.14%, with a current holding of 68.87% [2] - 医渡科技 (02158) decreased by -0.03%, now at 22.59% [2] - 盈富基金 (02800) saw a reduction of -0.02%, with a holding of 3.49% [2] - 山东墨龙 (00568) had a five-day decrease of -1.30%, now at 53.56% [5] - 亿华通 (02402) decreased by -1.00%, with a holding of 27.49% [5] - 国富氢能 (02582) saw a reduction of -0.90%, now at 20.14% [5] Group 3: Long-term Trends in Holdings - Over a 20-day period, 喜相逢集团 (02473) had the highest increase of 42.45%, reaching 45.14% [6] - 南方东西精选 (03441) increased by 27.31%, now at 41.03% [6] - 钧达股份 (02865) rose by 15.74%, with a holding of 64.80% [6] - 天齐锂业 (09696) experienced a significant decrease of -6.48%, now at 31.50% [6] - 金风科技 (02208) decreased by -5.88%, with a holding of 42.49% [6]

Core Insights - Yidu Tech has launched the "Yidu Smart Cycle" clinical evidence AI tool, currently in the internal testing phase, aimed at meeting the real needs of clinical doctors and medical researchers [1][2] - The AI tool is built on a foundation of over 30,000 authoritative sources selected from more than 40,000 guidelines and integrates over 5 million high-quality research outcomes from 30 million documents [1] - The tool has been validated through clinical trials with over 100,000 real clinical cases, achieving decision-making levels close to that of chief physicians [1] Company Developments - The internal testing phase involves frontline doctors with real practice backgrounds to provide feedback for optimizing the product's clinical utility [2] - There are plans to launch an app version to reach a broader audience of doctors [2] - The product aims to address the growing importance of evidence-based medicine in clinical decision-making and seeks to fill a market gap in high-quality clinical evidence AI in China [2]

Core Insights - Yidu Tech has launched the "Yidu Smart Evidence" clinical evidence AI tool, currently in internal testing, aimed at meeting the real needs of clinicians and researchers [1][2] - The AI tool is built on a foundation of over 30,000 authoritative sources selected from more than 40,000 guidelines and integrates over 5 million high-quality research outcomes from 30 million documents [1] - The tool has been validated with over 100,000 real clinical cases and has shown decision-making capabilities close to that of chief physicians in authoritative clinical evaluations [1] Group 1 - The "Yidu Smart Evidence" tool focuses on transforming medical documents into computable atomic knowledge, accurately identifying clinical needs and providing evidence-based references while minimizing AI hallucinations [1] - The internal testing involves frontline clinicians to optimize the product's clinical practicality, with plans to launch an app version to reach more doctors [2] - The increasing importance of evidence-based medicine in clinical decision-making positions "Yidu Smart Evidence" as a localized innovation comparable to OpenEvidence, with potential for a sustainable business model in the high-quality clinical evidence AI market in China [2]

另据可靠消息，医渡科技临床循证智能体"医渡智循"已开启内测。据了解，该产品专为临床医生与医学 研究者打造，聚焦临床诊疗和科研场景的真实需求，本次内测邀请具备真实执业背景的一线医生参与， 通过真实执业场景的反馈进一步优化产品临床实用性。此前其打造的"医生Copilot"在单院实现日均被调 用近千次，覆盖了约70%的临床医护人员，成为医生诊疗全程的得力伙伴，"医渡智循"的推出进一步丰 富了其智能体产品矩阵。 当前AI医疗行业政策与技术双轮驱动，国家八部门联合印发的《"人工智能+医疗卫生"应用发展实施意 见》中明确2030年实现二级以上医院智能辅助诊断全覆盖，临床循证类工具成为行业刚需。医渡科技一 边以持续回购传递价值认可，一边加速产品创新落地，其在AI医疗赛道的竞争力持续夯实，长期发展 值得期待。 智通财经APP获悉，2月24日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.96港元的 价格回购72万股，总耗资近430万港元，延续2026年以来的密集回购节奏。自1月26日以来，公司已完成 17次回购，累计斥资超7200万港元，以持续的资本动作彰显对自身发展及行业前景的双重信心。 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at clinical doctors and medical researchers, focusing on real-world clinical and research needs [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical usability based on actual feedback [1]. - The previously developed "Doctor Copilot" tool has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a joint issuance from eight national departments outlining plans for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and reinforce its competitive edge in the AI healthcare sector [1].